Vascular Biogenics analyst ratings
Vascular Biogenics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/20/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 07/18/2022 | 168.29% | Oppenheimer | → $5.5 | Assumes | → Outperform |
| 04/28/2022 | 143.9% | Chardan Capital | → $5 | Initiates Coverage On | → Buy |
| 06/03/2021 | 241.46% | Roth Capital | $5 → $7 | Maintains | Buy |
| 01/28/2021 | 95.12% | HC Wainwright & Co. | $3 → $4 | Maintains | Buy |
| 04/17/2020 | 46.34% | Oppenheimer | $2 → $3 | Maintains | Outperform |
| 06/27/2019 | -2.44% | Oppenheimer | → $2 | Initiates Coverage On | → Outperform |
| 10/15/2018 | 46.34% | HC Wainwright & Co. | $3 → $3 | Upgrades | Neutral → Buy |
| 03/09/2018 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 03/08/2018 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 07/20/2022 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 07/18/2022 | 168.29% | 奥本海默 | →$5.5 | 假设 | →跑赢大盘 |
| 04/28/2022 | 143.9% | 查尔丹资本 | →$5 | 开始承保 | →购买 |
| 06/03/2021 | 241.46% | 罗斯资本 | $5→$7 | 维护 | 买 |
| 2021年1月28日 | 95.12% | HC Wainwright公司 | $3→$4 | 维护 | 买 |
| 04/17/2020 | 46.34% | 奥本海默 | $2→$3 | 维护 | 跑赢大盘 |
| 2019年06月27日 | -2.44% | 奥本海默 | →$2 | 开始承保 | →跑赢大盘 |
| 2018年10月15日 | 46.34% | HC Wainwright公司 | $3→$3 | 升级 | 中性→购买 |
| 2018年03月09日 | - | 查尔丹资本 | 评级下调 | 购买→中性 | |
| 2018年03月08日 | - | HC Wainwright公司 | 评级下调 | 购买→中性 |
Vascular Biogenics Questions & Answers
血管生物遗传学问答
The latest price target for Vascular Biogenics (NASDAQ: VBLT) was reported by HC Wainwright & Co. on July 20, 2022. The analyst firm set a price target for $0.00 expecting VBLT to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
血管生物制药公司(纳斯达克代码：VBLT)的最新目标价是由HC Wainwright&Co.于2022年7月20日报道的。这家分析公司将目标价定为0.00美元，预计VBLT将在12个月内降至(可能下跌-100.00%)。3家分析公司在过去一年公布了评级。
The latest analyst rating for Vascular Biogenics (NASDAQ: VBLT) was provided by HC Wainwright & Co., and Vascular Biogenics downgraded their neutral rating.
对血管生物制药公司(纳斯达克代码：VBLT)的最新分析师评级由HC Wainwright&Co.提供，血管生物制药公司下调了其中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vascular Biogenics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vascular Biogenics was filed on July 20, 2022 so you should expect the next rating to be made available sometime around July 20, 2023.
分析师在进行了广泛的研究后，才得出股票评级，其中包括查阅公开财务报表，与血管生物基因公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。血管生物遗传公司的上一次评级是在2022年7月20日提交的，所以你应该预计下一次评级将在2023年7月20日左右的某个时候公布。
While ratings are subjective and will change, the latest Vascular Biogenics (VBLT) rating was a downgraded with a price target of $0.00 to $0.00. The current price Vascular Biogenics (VBLT) is trading at is $2.05, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的血管生物制药(VBLT)评级被下调，目标价为0.00美元至0.00美元。血管生物制药(VBLT)目前的交易价格为2.05美元，超出了分析师的预测范围。